APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Community-acquired Bacterial Pneumonia

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Community-acquired Bacterial Pneumonia Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025197 pages

Choose your research edition.

Industry ResearchCommunity-acquired Bacterial Pneumonia Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Community-acquired Bacterial Pneumonia Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Community-acquired Bacterial Pneumonia Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Community-acquired Bacterial Pneumonia Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Community-acquired Bacterial Pneumonia Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Community-acquired Bacterial Pneumonia market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Community-acquired Bacterial Pneumonia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Community-acquired Bacterial Pneumonia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Community-acquired Bacterial Pneumonia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Community-acquired Bacterial Pneumonia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Community-acquired Bacterial Pneumonia include Takeda Pharmaceutical Company Limited, Sanofi S.A., Mylan N.V., Pfizer Inc., Bayer AG, Paratek Pharmaceuticals, Nabriva Therapeutics, Melinta Therapeutics and Lupin Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Community-acquired Bacterial Pneumonia market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Community-acquired Bacterial Pneumonia and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Community-acquired Bacterial Pneumonia revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Community-acquired Bacterial Pneumonia market size, projected growth trends, production technologies, key applications, and end-use industries.

Community-acquired Bacterial Pneumonia Segment by Company

Takeda Pharmaceutical Company Limited

Sanofi S.A.

Mylan N.V.

Pfizer Inc.

Bayer AG

Paratek Pharmaceuticals

Nabriva Therapeutics

Melinta Therapeutics

Lupin Pharmaceuticals

Dainippon Sumitomo Pharma

Basilea Pharmaceutica International AG

Allergan plc

Community-acquired Bacterial Pneumonia Segment by Type

Oxazolidinone

Glycylcycline

Pleuromutilin Antibiotic

Ketolide

Cephalosporin

Others

Community-acquired Bacterial Pneumonia Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Community-acquired Bacterial Pneumonia Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Community-acquired Bacterial Pneumonia market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Community-acquired Bacterial Pneumonia and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Community-acquired Bacterial Pneumonia.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Community-acquired Bacterial Pneumonia in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Community-acquired Bacterial Pneumonia industry.

Chapter 3: Detailed analysis of Community-acquired Bacterial Pneumonia companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Community-acquired Bacterial Pneumoniarevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Community-acquired Bacterial Pneumonia Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Oxazolidinone Table 3. Key Players of Glycylcycline Table 4. Key Players of Pleuromutilin Antibiotic Table 3. Key Players of Ketolide Table 4. Key Players of Cephalosporin Table 5. Key Players of Others Table 6. Global Community-acquired Bacterial Pneumonia Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 7. Key Players of Retail Pharmacies Table 8. Key Players of Online Pharmacies Table 9. Key Players of Hospital Pharmacies Table 10. Global Community-acquired Bacterial Pneumonia Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 11. Global Community-acquired Bacterial Pneumonia Market Size by Region (2021-2026) & (US$ Million) Table 12. Global Community-acquired Bacterial Pneumonia Market Share by Region (2021-2026) Table 13. Global Community-acquired Bacterial Pneumonia Market Size by Region (2027-2032) & (US$ Million) Table 14. Global Community-acquired Bacterial Pneumonia Market Share by Region (2027-2032) Table 15. Community-acquired Bacterial Pneumonia Industry Trends Table 16. Community-acquired Bacterial Pneumonia Industry Drivers Table 17. Community-acquired Bacterial Pneumonia Industry Opportunities and Challenges Table 18. Community-acquired Bacterial Pneumonia Industry Restraints Table 19. Global Community-acquired Bacterial Pneumonia Revenue by Company (US$ Million) & (2021-2026) Table 20. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Company (2021-2026) Table 21. Global Community-acquired Bacterial Pneumonia Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 22. Global Community-acquired Bacterial Pneumonia Key Company Head Office and Area Served Table 23. Global Community-acquired Bacterial Pneumonia Company, Product Type & Application Table 24. Global Community-acquired Bacterial Pneumonia Company Establishment Date Table 25. Global Company Market Concentration Ratio (CR5 and HHI) Table 26. Global Community-acquired Bacterial Pneumonia by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 27. Global Community-acquired Bacterial Pneumonia Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Community-acquired Bacterial Pneumonia Market Size by Type (2021-2026) & (US$ Million) Table 29. Global Community-acquired Bacterial Pneumonia Market Size by Type (2027-2032) & (US$ Million) Table 30. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2021-2026) Table 31. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2027-2032) Table 32. Global Community-acquired Bacterial Pneumonia Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Community-acquired Bacterial Pneumonia Market Size by Application (2021-2026) & (US$ Million) Table 34. Global Community-acquired Bacterial Pneumonia Market Size by Application (2027-2032) & (US$ Million) Table 35. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2021-2026) Table 36. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2027-2032) Table 37. Takeda Pharmaceutical Company Limited Company Information Table 38. Takeda Pharmaceutical Company Limited Business Overview Table 39. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product Portfolio Table 41. Takeda Pharmaceutical Company Limited Recent Development Table 42. Sanofi S.A. Company Information Table 43. Sanofi S.A. Business Overview Table 44. Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Sanofi S.A. Community-acquired Bacterial Pneumonia Product Portfolio Table 46. Sanofi S.A. Recent Development Table 47. Mylan N.V. Company Information Table 48. Mylan N.V. Business Overview Table 49. Mylan N.V. Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Mylan N.V. Community-acquired Bacterial Pneumonia Product Portfolio Table 51. Mylan N.V. Recent Development Table 52. Pfizer Inc. Company Information Table 53. Pfizer Inc. Business Overview Table 54. Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Pfizer Inc. Community-acquired Bacterial Pneumonia Product Portfolio Table 56. Pfizer Inc. Recent Development Table 57. Bayer AG Company Information Table 58. Bayer AG Business Overview Table 59. Bayer AG Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Bayer AG Community-acquired Bacterial Pneumonia Product Portfolio Table 61. Bayer AG Recent Development Table 62. Paratek Pharmaceuticals Company Information Table 63. Paratek Pharmaceuticals Business Overview Table 64. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product Portfolio Table 66. Paratek Pharmaceuticals Recent Development Table 67. Nabriva Therapeutics Company Information Table 68. Nabriva Therapeutics Business Overview Table 69. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product Portfolio Table 71. Nabriva Therapeutics Recent Development Table 72. Melinta Therapeutics Company Information Table 73. Melinta Therapeutics Business Overview Table 74. Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Melinta Therapeutics Community-acquired Bacterial Pneumonia Product Portfolio Table 76. Melinta Therapeutics Recent Development Table 77. Lupin Pharmaceuticals Company Information Table 78. Lupin Pharmaceuticals Business Overview Table 79. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product Portfolio Table 81. Lupin Pharmaceuticals Recent Development Table 82. Dainippon Sumitomo Pharma Company Information Table 83. Dainippon Sumitomo Pharma Business Overview Table 84. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product Portfolio Table 86. Dainippon Sumitomo Pharma Recent Development Table 87. Basilea Pharmaceutica International AG Company Information Table 88. Basilea Pharmaceutica International AG Business Overview Table 89. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 90. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product Portfolio Table 91. Basilea Pharmaceutica International AG Recent Development Table 92. Allergan plc Company Information Table 93. Allergan plc Business Overview Table 94. Allergan plc Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 95. Allergan plc Community-acquired Bacterial Pneumonia Product Portfolio Table 96. Allergan plc Recent Development Table 97. North America Community-acquired Bacterial Pneumonia Market Size by Type (2021-2026) & (US$ Million) Table 98. North America Community-acquired Bacterial Pneumonia Market Size by Type (2027-2032) & (US$ Million) Table 99. North America Community-acquired Bacterial Pneumonia Market Size by Application (2021-2026) & (US$ Million) Table 100. North America Community-acquired Bacterial Pneumonia Market Size by Application (2027-2032) & (US$ Million) Table 101. North America Community-acquired Bacterial Pneumonia Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. North America Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026) Table 103. North America Community-acquired Bacterial Pneumonia Market Size by Country (2027-2032) Table 104. Europe Community-acquired Bacterial Pneumonia Market Size by Type (2021-2026) & (US$ Million) Table 105. Europe Community-acquired Bacterial Pneumonia Market Size by Type (2027-2032) & (US$ Million) Table 106. Europe Community-acquired Bacterial Pneumonia Market Size by Application (2021-2026) & (US$ Million) Table 107. Europe Community-acquired Bacterial Pneumonia Market Size by Application (2027-2032) & (US$ Million) Table 108. Europe Community-acquired Bacterial Pneumonia Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. Europe Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026) Table 110. Europe Community-acquired Bacterial Pneumonia Market Size by Country (2027-2032) Table 111. China Community-acquired Bacterial Pneumonia Market Size by Type (2021-2026) & (US$ Million) Table 112. China Community-acquired Bacterial Pneumonia Market Size by Type (2027-2032) & (US$ Million) Table 113. China Community-acquired Bacterial Pneumonia Market Size by Application (2021-2026) & (US$ Million) Table 114. China Community-acquired Bacterial Pneumonia Market Size by Application (2027-2032) & (US$ Million) Table 115. Asia Community-acquired Bacterial Pneumonia Market Size by Type (2021-2026) & (US$ Million) Table 116. Asia Community-acquired Bacterial Pneumonia Market Size by Type (2027-2032) & (US$ Million) Table 117. Asia Community-acquired Bacterial Pneumonia Market Size by Application (2021-2026) & (US$ Million) Table 118. Asia Community-acquired Bacterial Pneumonia Market Size by Application (2027-2032) & (US$ Million) Table 119. Asia Community-acquired Bacterial Pneumonia Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. Asia Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026) Table 121. Asia Community-acquired Bacterial Pneumonia Market Size by Country (2027-2032) Table 122. South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Type (2021-2026) & (US$ Million) Table 123. South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Type (2027-2032) & (US$ Million) Table 124. South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Application (2021-2026) & (US$ Million) Table 125. South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Application (2027-2032) & (US$ Million) Table 126. South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026) Table 128. South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2027-2032) Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Community-acquired Bacterial Pneumonia Product Image Figure 2. Global Community-acquired Bacterial Pneumonia Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Community-acquired Bacterial Pneumonia Market Share by Type: 2025 VS 2032 Figure 4. Oxazolidinone Image Figure 5. Glycylcycline Image Figure 6. Pleuromutilin Antibiotic Image Figure 7. Ketolide Image Figure 8. Cephalosporin Image Figure 9. Others Image Figure 10. Global Community-acquired Bacterial Pneumonia Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 11. Global Community-acquired Bacterial Pneumonia Market Share by Application: 2025 VS 2032 Figure 12. Retail Pharmacies Image Figure 13. Online Pharmacies Image Figure 14. Hospital Pharmacies Image Figure 15. Global Community-acquired Bacterial Pneumonia Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 17. Global Community-acquired Bacterial Pneumonia Market Share by Region: 2025 VS 2032 Figure 18. Years Considered Figure 19. Global Community-acquired Bacterial Pneumonia Market Share by Players in 2025 Figure 20. Global Top 5 and 10 Community-acquired Bacterial Pneumonia Players Market Share by Revenue in 2025 Figure 21. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Community-acquired Bacterial Pneumonia Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2021-2032) Figure 24. Global Community-acquired Bacterial Pneumonia Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2021-2032) Figure 26. North America Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 27. North America Community-acquired Bacterial Pneumonia Market Share by Type (2021-2032) Figure 28. North America Community-acquired Bacterial Pneumonia Market Share by Application (2021-2032) Figure 29. North America Community-acquired Bacterial Pneumonia Market Share by Country (2021-2032) Figure 30. United States Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 31. Canada Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 32. Mexico Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 33. Europe Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 34. Europe Community-acquired Bacterial Pneumonia Market Share by Type (2021-2032) Figure 35. Europe Community-acquired Bacterial Pneumonia Market Share by Application (2021-2032) Figure 36. Europe Community-acquired Bacterial Pneumonia Market Share by Country (2021-2032) Figure 37. Germany Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 38. France Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 39. U.K. Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 40. Italy Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 41. Russia Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 42. Nordic Countries Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 43. China Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 44. China Community-acquired Bacterial Pneumonia Market Share by Type (2021-2032) Figure 45. China Community-acquired Bacterial Pneumonia Market Share by Application (2021-2032) Figure 46. Asia Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 47. Asia Community-acquired Bacterial Pneumonia Market Share by Type (2021-2032) Figure 48. Asia Community-acquired Bacterial Pneumonia Market Share by Application (2021-2032) Figure 49. Asia Community-acquired Bacterial Pneumonia Market Share by Country (2021-2032) Figure 50. Japan Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 51. South Korea Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 52. Taiwan Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 53. Southeast Asia Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 54. India Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 55. Australia Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 57. South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Share by Type (2021-2032) Figure 58. South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Share by Application (2021-2032) Figure 59. South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Share by Country (2021-2032) Figure 60. Brazil Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 61. South Africa Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 62. Saudi Arabia Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 63. Turkey Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 64. Argentina Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 65. UAE Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 66. Egypt Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 67. Chile Community-acquired Bacterial Pneumonia Market Size (2021-2032) & (US$ Million) Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Oxazolidinone
  • Glycylcycline
  • Pleuromutilin Antibiotic
  • Ketolide
  • Cephalosporin
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Takeda Pharmaceutical Company Limited
  • Sanofi S.A.
  • Mylan N.V.
  • Pfizer Inc.
  • Bayer AG
  • Paratek Pharmaceuticals
  • Nabriva Therapeutics
  • Melinta Therapeutics
  • Lupin Pharmaceuticals
  • Dainippon Sumitomo Pharma
  • Basilea Pharmaceutica International AG
  • Allergan plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Community-acquired Bacterial Pneumonia Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Oxazolidinone
  5. 1.2.3 Glycylcycline
  6. 1.2.4 Pleuromutilin Antibiotic
  7. 1.2.5 Ketolide
  8. 1.2.6 Cephalosporin
  9. 1.2.7 Others
  10. 1.3 Market Analysis by Application
  11. 1.3.1 Global Community-acquired Bacterial Pneumonia Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  12. 1.3.2 Retail Pharmacies
  13. 1.3.3 Online Pharmacies
  14. 1.3.4 Hospital Pharmacies
  15. 1.4 Global Market Growth Prospects
  16. 1.5 Global Community-acquired Bacterial Pneumonia Growth Trends by Region
  17. 1.5.1 Global Community-acquired Bacterial Pneumonia Market Size by Region: 2021 VS 2025 VS 2032
  18. 1.5.2 Community-acquired Bacterial Pneumonia Market Size by Region (2021-2026)
  19. 1.5.3 Community-acquired Bacterial Pneumonia Market Size by Region (2027-2032)
  20. 1.6 Assumptions and Limitations
  21. 1.7 Study Goals and Objectives
  22. 1.8 Years Considered
2 Global Community-acquired Bacterial Pneumonia Market Dynamics
  1. 2.1 Community-acquired Bacterial Pneumonia Industry Trends
  2. 2.2 Community-acquired Bacterial Pneumonia Industry Drivers
  3. 2.3 Community-acquired Bacterial Pneumonia Industry Opportunities and Challenges
  4. 2.4 Community-acquired Bacterial Pneumonia Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Community-acquired Bacterial Pneumonia Revenue by Company (2021-2026)
  2. 3.2 Global Community-acquired Bacterial Pneumonia Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Community-acquired Bacterial Pneumonia Key Company Head office and Area Served
  4. 3.4 Global Community-acquired Bacterial Pneumonia Company, Product Type & Application
  5. 3.5 Global Community-acquired Bacterial Pneumonia Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Community-acquired Bacterial Pneumonia Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Community-acquired Bacterial Pneumonia Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Community-acquired Bacterial Pneumonia Tier 1, Tier 2, and Tier 3
4 Community-acquired Bacterial Pneumonia Market by Type
  1. 4.1 Global Community-acquired Bacterial Pneumonia Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Community-acquired Bacterial Pneumonia Market Size by Type (2021-2032)
  3. 4.3 Global Community-acquired Bacterial Pneumonia Market Size Share by Type (2021-2032)
5 Community-acquired Bacterial Pneumonia Market by Application
  1. 5.1 Global Community-acquired Bacterial Pneumonia Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Community-acquired Bacterial Pneumonia Market Size by Application (2021-2032)
  3. 5.3 Global Community-acquired Bacterial Pneumonia Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Takeda Pharmaceutical Company Limited
  2. 6.1.1 Takeda Pharmaceutical Company Limited Company Information
  3. 6.1.2 Takeda Pharmaceutical Company Limited Business Overview
  4. 6.1.3 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product Portfolio
  6. 6.1.5 Takeda Pharmaceutical Company Limited Recent Developments
  7. 6.2 Sanofi S.A.
  8. 6.2.1 Sanofi S.A. Company Information
  9. 6.2.2 Sanofi S.A. Business Overview
  10. 6.2.3 Sanofi S.A. Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Sanofi S.A. Community-acquired Bacterial Pneumonia Product Portfolio
  12. 6.2.5 Sanofi S.A. Recent Developments
  13. 6.3 Mylan N.V.
  14. 6.3.1 Mylan N.V. Company Information
  15. 6.3.2 Mylan N.V. Business Overview
  16. 6.3.3 Mylan N.V. Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Mylan N.V. Community-acquired Bacterial Pneumonia Product Portfolio
  18. 6.3.5 Mylan N.V. Recent Developments
  19. 6.4 Pfizer Inc.
  20. 6.4.1 Pfizer Inc. Company Information
  21. 6.4.2 Pfizer Inc. Business Overview
  22. 6.4.3 Pfizer Inc. Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Pfizer Inc. Community-acquired Bacterial Pneumonia Product Portfolio
  24. 6.4.5 Pfizer Inc. Recent Developments
  25. 6.5 Bayer AG
  26. 6.5.1 Bayer AG Company Information
  27. 6.5.2 Bayer AG Business Overview
  28. 6.5.3 Bayer AG Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Bayer AG Community-acquired Bacterial Pneumonia Product Portfolio
  30. 6.5.5 Bayer AG Recent Developments
  31. 6.6 Paratek Pharmaceuticals
  32. 6.6.1 Paratek Pharmaceuticals Company Information
  33. 6.6.2 Paratek Pharmaceuticals Business Overview
  34. 6.6.3 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product Portfolio
  36. 6.6.5 Paratek Pharmaceuticals Recent Developments
  37. 6.7 Nabriva Therapeutics
  38. 6.7.1 Nabriva Therapeutics Company Information
  39. 6.7.2 Nabriva Therapeutics Business Overview
  40. 6.7.3 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product Portfolio
  42. 6.7.5 Nabriva Therapeutics Recent Developments
  43. 6.8 Melinta Therapeutics
  44. 6.8.1 Melinta Therapeutics Company Information
  45. 6.8.2 Melinta Therapeutics Business Overview
  46. 6.8.3 Melinta Therapeutics Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Melinta Therapeutics Community-acquired Bacterial Pneumonia Product Portfolio
  48. 6.8.5 Melinta Therapeutics Recent Developments
  49. 6.9 Lupin Pharmaceuticals
  50. 6.9.1 Lupin Pharmaceuticals Company Information
  51. 6.9.2 Lupin Pharmaceuticals Business Overview
  52. 6.9.3 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product Portfolio
  54. 6.9.5 Lupin Pharmaceuticals Recent Developments
  55. 6.10 Dainippon Sumitomo Pharma
  56. 6.10.1 Dainippon Sumitomo Pharma Company Information
  57. 6.10.2 Dainippon Sumitomo Pharma Business Overview
  58. 6.10.3 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product Portfolio
  60. 6.10.5 Dainippon Sumitomo Pharma Recent Developments
  61. 6.11 Basilea Pharmaceutica International AG
  62. 6.11.1 Basilea Pharmaceutica International AG Company Information
  63. 6.11.2 Basilea Pharmaceutica International AG Business Overview
  64. 6.11.3 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product Portfolio
  66. 6.11.5 Basilea Pharmaceutica International AG Recent Developments
  67. 6.12 Allergan plc
  68. 6.12.1 Allergan plc Company Information
  69. 6.12.2 Allergan plc Business Overview
  70. 6.12.3 Allergan plc Community-acquired Bacterial Pneumonia Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Allergan plc Community-acquired Bacterial Pneumonia Product Portfolio
  72. 6.12.5 Allergan plc Recent Developments
7 North America
  1. 7.1 North America Community-acquired Bacterial Pneumonia Market Size (2021-2032)
  2. 7.2 North America Community-acquired Bacterial Pneumonia Market Size by Type
  3. 7.2.1 North America Community-acquired Bacterial Pneumonia Market Size by Type (2021-2026)
  4. 7.2.2 North America Community-acquired Bacterial Pneumonia Market Size by Type (2027-2032)
  5. 7.2.3 North America Community-acquired Bacterial Pneumonia Market Share by Type (2021-2032)
  6. 7.3 North America Community-acquired Bacterial Pneumonia Market Size by Application
  7. 7.3.1 North America Community-acquired Bacterial Pneumonia Market Size by Application (2021-2026)
  8. 7.3.2 North America Community-acquired Bacterial Pneumonia Market Size by Application (2027-2032)
  9. 7.3.3 North America Community-acquired Bacterial Pneumonia Market Share by Application (2021-2032)
  10. 7.4 North America Community-acquired Bacterial Pneumonia Market Size by Country
  11. 7.4.1 North America Community-acquired Bacterial Pneumonia Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026)
  13. 7.4.3 North America Community-acquired Bacterial Pneumonia Market Size by Country (2027-2032)
  14. 7.4.4 North America Community-acquired Bacterial Pneumonia Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Community-acquired Bacterial Pneumonia Market Size (2021-2032)
  2. 8.2 Europe Community-acquired Bacterial Pneumonia Market Size by Type
  3. 8.2.1 Europe Community-acquired Bacterial Pneumonia Market Size by Type (2021-2026)
  4. 8.2.2 Europe Community-acquired Bacterial Pneumonia Market Size by Type (2027-2032)
  5. 8.2.3 Europe Community-acquired Bacterial Pneumonia Market Share by Type (2021-2032)
  6. 8.3 Europe Community-acquired Bacterial Pneumonia Market Size by Application
  7. 8.3.1 Europe Community-acquired Bacterial Pneumonia Market Size by Application (2021-2026)
  8. 8.3.2 Europe Community-acquired Bacterial Pneumonia Market Size by Application (2027-2032)
  9. 8.3.3 Europe Community-acquired Bacterial Pneumonia Market Share by Application (2021-2032)
  10. 8.4 Europe Community-acquired Bacterial Pneumonia Market Size by Country
  11. 8.4.1 Europe Community-acquired Bacterial Pneumonia Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026)
  13. 8.4.3 Europe Community-acquired Bacterial Pneumonia Market Size by Country (2027-2032)
  14. 8.4.4 Europe Community-acquired Bacterial Pneumonia Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Community-acquired Bacterial Pneumonia Market Size (2021-2032)
  2. 9.2 China Community-acquired Bacterial Pneumonia Market Size by Type
  3. 9.2.1 China Community-acquired Bacterial Pneumonia Market Size by Type (2021-2026)
  4. 9.2.2 China Community-acquired Bacterial Pneumonia Market Size by Type (2027-2032)
  5. 9.2.3 China Community-acquired Bacterial Pneumonia Market Share by Type (2021-2032)
  6. 9.3 China Community-acquired Bacterial Pneumonia Market Size by Application
  7. 9.3.1 China Community-acquired Bacterial Pneumonia Market Size by Application (2021-2026)
  8. 9.3.2 China Community-acquired Bacterial Pneumonia Market Size by Application (2027-2032)
  9. 9.3.3 China Community-acquired Bacterial Pneumonia Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Community-acquired Bacterial Pneumonia Market Size (2021-2032)
  2. 10.2 Asia Community-acquired Bacterial Pneumonia Market Size by Type
  3. 10.2.1 Asia Community-acquired Bacterial Pneumonia Market Size by Type (2021-2026)
  4. 10.2.2 Asia Community-acquired Bacterial Pneumonia Market Size by Type (2027-2032)
  5. 10.2.3 Asia Community-acquired Bacterial Pneumonia Market Share by Type (2021-2032)
  6. 10.3 Asia Community-acquired Bacterial Pneumonia Market Size by Application
  7. 10.3.1 Asia Community-acquired Bacterial Pneumonia Market Size by Application (2021-2026)
  8. 10.3.2 Asia Community-acquired Bacterial Pneumonia Market Size by Application (2027-2032)
  9. 10.3.3 Asia Community-acquired Bacterial Pneumonia Market Share by Application (2021-2032)
  10. 10.4 Asia Community-acquired Bacterial Pneumonia Market Size by Country
  11. 10.4.1 Asia Community-acquired Bacterial Pneumonia Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026)
  13. 10.4.3 Asia Community-acquired Bacterial Pneumonia Market Size by Country (2027-2032)
  14. 10.4.4 Asia Community-acquired Bacterial Pneumonia Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Community-acquired Bacterial Pneumonia Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst